No Data
SanBio - With a purchasing atmosphere of limit up, new US patents for their major development product "SB623" have been approved.
There is a buying atmosphere of limit-up. After the close of trading on the 25th, it was announced that a new patent related to the cell therapy of chronic cerebral infarction using the main development product "SB623" has been granted in the United States, which is considered to be good news. As part of maximizing corporate value, the company is striving to build and maintain a patent portfolio, but with this patent acquisition, the period of application patent for the treatment of chronic cerebral infarction with"SB623" in the largest market, the United States, has been significantly extended.
It is a strong and easy to buy on dips, but there is a heavy resistance to upward movement.
[Emerging Markets Individual Stock Strategies] Today's emerging markets are expected to have a solid development. In the US stock market on the 25th yesterday, the Dow Jones Industrial Average rebounded for the first time in three days, up 81.20 points (+0.20%) to 39,935.07 points. The pessimistic view on the economy has retreated due to the better-than-expected growth in domestic GDP in the April-June quarter, which supported the stock prices. However, the profit-taking selling ahead of the announcement of the important inflation indicators restrained the upside, and the high-tech sector was weak and slowed down towards the end, with the Nasdaq composite index...
Kinciro, Sunbio, and other emerging market press releases.
<3727> APLIX has completed the buyback of its own shares. <4013> Kinjiro raises upward revision, with the first half operating profit expected to be 0.281 billion yen, up from 0.188 billion yen. <4588> OncoTherapy Science will issue a large number of shares exercised from the 20th subscription rights (with exercise price adjustment clause) starting from the 2nd, with a total of 0.57 million 1500 shares issued. <4592> SanBio's new patent has been approved in the United States for cell therapy for chronic cerebral infarction using the main development product SB623.
TOPIX Growth Market 250 Index Futures Overview: The afternoon session saw an expansion of the decline due to weekend factors.
On July 19, the Tokyo Stock Exchange Growth Market 250 index futures fell 15 points to 673 points compared to the previous trading day. The high was 685 points, the low was 671 points, and the daily trading volume was 8394 shares. On the previous day of July 17, the Dow Jones Industrial Average in the US market fell for the first time in seven days. After the opening, it fell due to higher-than-expected employment and manufacturing-related indicators, and the expectation of an early interest rate cut declined. In addition to profit-taking sales, the caution towards corporate earnings triggered further selling, and the Dow, which had been updating its record highs for consecutive days, expanded its losses towards the end. High-tech.
SanBio Reveals Breakthrough in Brain Regeneration Research
The Tokyo Stock Exchange's Gross Index has been slightly up for 4 consecutive days, generally showing a steady movement in the afternoon with active bioscience stock picking.
On the Growth Market of the Tokyo Stock Exchange, the market index rose slightly for the fourth consecutive day, with the Growth Market Index at 848.64 (+2.01) and a volume of 0.22417 billion shares, amounting to JPY 113.9 billion. The Growth Market 250 Index was also up slightly at 658.93 (+1.48), with a volume of 0.17788 billion shares traded for JPY 85.3 billion. There were 261 gainers, 278 losers, and 46 unchanged. The Dow Jones Industrial Average rose $67.87 in the U.S. market on the 5th day.
No Data
